# SUPPLEMENTARY FIGURES

Supplementary Figure 1. The differences in immune cell infiltration between the high-risk and low-risk groups according to the CIBERSORT (**A**) and TIMER algorithms (**B**). ($^{*}p < 0.05$; $^{**}p < 0.01$; $^{***}p < 0.001$; $^{****}p < 0.0001$; ns $p > 0.05$).

Supplementary Figure 2. Effect of the candidate drugs on CHMP4C knockdown cells. (**A**) CHMP4C expression in the control and siCHMP4C groups. (**B–F**) Viability of the cells in response to (**B**) trametinib, (**C**) dasatinib, (**D**) selumetinib, (**E**) SCH772984 and (**F**) PD0325901.

Supplementary Figure 3. Effect of the candidate drugs on JAK1 knockdown cells. (**A**) JAK1 expression in the control and siJAK1 groups. (**B–F**) Viability of the cells in response to (**B**) trametinib, (**C**) dasatinib, (**D**) selumetinib, (**E**) SCH772984 and (**F**) PD0325901.

Supplementary Figure 4. Effect of the candidate drugs on IL-β knockdown cells. (**A**) IL-β expression in the control and siIL-β groups. (**B–F**) Viability of the cells in response to (**B**) trametinib, (**C**) dasatinib, (**D**) selumetinib, (**E**) SCH772984 and (**F**) PD0325901.